| Title |
Benzodiazepines for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2012
|
| DOI | 10.1002/14651858.cd006391.pub2 |
| Pubmed ID | |
| Authors |
Markus Dold, Chunbo Li, Magdolna Tardy, Vesal Khorsand, Donna Gillies, Stefan Leucht |
| Abstract |
Because of the high number of people with schizophrenia not responding adequately to monotherapy with antipsychotic agents, the evidence regarding the efficacy and safety of additional medication was examined in a number of clinical trials. One approach to this research question was the use of benzodiazepines, as monotherapy as well as in combination with antipsychotics. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 23% |
| Australia | 1 | 8% |
| Ireland | 1 | 8% |
| France | 1 | 8% |
| Unknown | 7 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 54% |
| Scientists | 3 | 23% |
| Practitioners (doctors, other healthcare professionals) | 2 | 15% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 197 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Unknown | 195 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 30 | 15% |
| Student > Bachelor | 27 | 14% |
| Researcher | 19 | 10% |
| Student > Doctoral Student | 14 | 7% |
| Student > Postgraduate | 11 | 6% |
| Other | 33 | 17% |
| Unknown | 63 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 61 | 31% |
| Psychology | 20 | 10% |
| Nursing and Health Professions | 15 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
| Social Sciences | 7 | 4% |
| Other | 15 | 8% |
| Unknown | 70 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2023.
All research outputs
#1,722,152
of 23,495,502 outputs
Outputs from Cochrane database of systematic reviews
#3,936
of 12,711 outputs
Outputs of similar age
#11,427
of 180,783 outputs
Outputs of similar age from Cochrane database of systematic reviews
#76
of 245 outputs
Altmetric has tracked 23,495,502 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,711 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.0. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,783 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 245 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.